eagle-i eagle-i Network Shared Resource Repositoryeagle-i Network Shared Resource Repository
See it in Search

Cowan Lab

Summary:

About Cowan Lab's Next Gen Cell Lines

This collection, from Dr. Chad Cowan (Harvard Stem Cell Institute), was generated to confirm identified variants through differentiation of induced pluripotent stem cells to study cellular pathophysiology.

The Framingham Heart Study has provided knowledge about the epidemiology of hypertensive or arteriosclerotic cardiovascular disease. These cell lines may be useful in studying cardiovascular disease.

Peripheral blood mononuclear cells from 34 Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort participants were reprogrammed into iPSC lines. Upon initial deposit of this collection, 17 participants were homozygous for the major haplotype at the 1p13 locus and 17 participants were homozygous for the minor haplotype at the 1p13 locus. Two clones from each donor were further expanded resulting in a total of 68 iPSC lines. The focus of deriving these cell lines was to differentiate iPSC lines into hepatocytes and adipocytes to investigate the effect of the 1p13 rs12740374 variant on cardiometabolic disease phenotypes via transcriptomics and metabolomics signatures. The age of donors ranges from 51-90 years. To protect donor identity, an age range rather than exact age is provided.

Please see Table S1 from the publication describing this collection of cell lines for additional information on these cell lines including:
• 1p13 Genotype
• Average Adipocyte Differentiation Efficiency
• Average Hepatocyte-like Cells (HLC) Differentiation Efficiency

Application to and approval by the Framingham Heart Study is necessary to receive these cell lines. You can being your research application here.

About the Next Generation Genetic Association Studies (Next Gen) Program

These cell lines were created as Next Generation Genetic Association Studies (Next Gen) Program, which was a five-year, $80 million program to investigate functional genetic variation in humans by assessing cellular profiles that are surrogates for disease phenotypes. To achieve this, researchers from multiple institutions across the U.S. were awarded grants to derive iPS cell lines from more than 1,500 individuals representing various conditions as well as healthy controls for use in functional genomic (‘disease in a dish’) research. This extensive panel includes a diverse set of age, gender and ethnic backgrounds, and therefore will be an invaluable tool for evaluations across demographics. Further enhancing the utility of these cell lines are data sets such as phenotyping, GWAS, genome sequencing, gene expression and -omics analyses (e.g., lipidomic, proteomic, methylomic) that will be made available with the cell lines.

Affiliations:

People:

Resources:

Human Studies

  • INTEGRATING LIPID GENOTYES AND PHENOTYPES IN IPS DERIVED HEPATOCYTES/ADIPOCYTES ( Human Study )

    The discovery of new and effective treatments for human cardiovascular diseases requires the Identification and validation of novel disease mechanisms. Recently, studies of genomic variation entered a new phase. in which unbiased genome-wide association studies (GWAS) can identify novel genetic loci associated with common diseases. We have recently described 95 loci associate with blood lipid levels-LDL cholesterol (LDL-C), HDL Cholesterol (HDL-C), or triglycerides, which are strongly associated with risk for Myocardial Infarction (Ml) in the NHLBl Framingham Heart Study (FHS) and other population cohorts. Much work will be needed to convert the novel associations into functional insights and, ultimately, therapies to reduce the risk of Ml. A key step is to determine how these genetic loci affect phenotypes in human tissue types relevant to lipid metabolism, principally liver and adipose. We have performed expression quantitative trait locus (eQTL) analyses of genotype vs. gene expression in Surgical liver and adipose tissue samples from patients; from this work, we found a strong association between an LDL-C- and Ml-associated SNP on chromosome 1p13-rs12740374-and hepatic expression of the S0RT1 gene. However, these studies were limited by scarcity of tissue and the inability to address key cellular phenotypes such as lipoprotein secretion. Thus, there is a need to establish infinitely renewable sources of hepatocytes and adipocytes from patients of defined genotypes. We have developed the ability to obtain reprogrammed induced pluripotent stem (iPS) cells via peripheral blood cell (PBC) collection. We have also developed a novel technology to accelerate and scale up iPS generation, without any genomic alteration, using in vitro transcribed RNAs encoding reprogramming factors. Finally, we have established protocols to differentiate iPS cells into functional hepatocytes and adipocytes. Our consortium comprises Investigators from the FHS, the Harvard Stem Cell Institute (HSCI), Massachusetts General Hospital (MGH), and Harvard Medical School (HMS). We are uniquely positioned to develop a library of iPS cell lines and iPS- derived hepatocytes and adipocytes from several hundred FHS participants, who have genome-wide genotype data as well as many cardiovascular phenotypes. We propose to leverage these resources to: (1) develop efficient protocols to obtain iPS cell lines from blood samples, followed by differentiation into functional hepatocytes and adipocytes; (2) scale up these protocols to enable high-throughput generation of iPS cell lines, hepatocytes, and adipocytes from ~400 Individuals in the Framingham offspring Cohort; and (3) perform gene expression and metaboiomic profiling from these hepatocytes and adipocytes, enabling Integrative statistical analyses of genotypes with gene expression and metabolite levels, as well as existing phenotype data such as subclinical measures of atherosclerosis.

Reagents

  • FHS001i-sh10950A ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS002i-sh10950C) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS002i-sh10950C ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS001i-sh10950A) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS003i-sh12022B ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS004i-sh12022C) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS004i-sh12022C ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS003i-sh12022B) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS005i-sh1236B ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS006i-sh1236C) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS006i-sh1236C ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS005i-sh1236B) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS007i-sh12569A ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS008i-sh12569B) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS008i-sh12569B ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS007i-sh12569A) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS009i-sh12888A ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS010i-sh12888B) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS010i-sh12888B ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS009i-sh12888A) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS011i-sh1293A ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS012i-sh1293B) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS012i-sh1293B ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS011i-sh1293A) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS013i-sh1296C ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS014i-sh1296E) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS014i-sh1296E ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS013i-sh1296C) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS015i-sh13352A ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS016i-sh13352E) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS016i-sh13352E ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS015i-sh13352A) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS017i-sh14157A ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS018i-sh14157C) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS018i-sh14157C ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS017i-sh14157A) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS019i-sh1441F ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS020i-sh1441G) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS020i-sh1441G ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS019i-sh1441F) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS021i-sh14685A ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS022i-sh14685B) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS022i-sh14685B ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS021i-sh14685A) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS023i-sh16126C ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS024i-sh16126E) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS024i-sh16126E ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS023i-sh16126C) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS025i-sh1649A ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS026i-sh1649B) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS026i-sh1649B ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS025i-sh1649A) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS027i-sh1660E ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS028i-sh1660F) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS028i-sh1660F ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS027i-sh1660E) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS029i-sh1673B ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS030i-sh1673F) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS030i-sh1673F ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS029i-sh1673B) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS031i-sh16939A ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS032i-sh16939B) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS032i-sh16939B ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS031i-sh16939A) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS033i-sh18719B ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS034i-sh18719D) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS034i-sh18719D ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS033i-sh18719B) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS035i-sh18961A ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS036i-sh18961C) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS036i-sh18961C ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS035i-sh18961A) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS037i-sh1998E ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS038i-sh1998G) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS038i-sh1998G ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS037i-sh1998E) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS039i-sh2098A ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS040i-sh2098B) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS040i-sh2098B ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS039i-sh2098A) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS041i-sh22512A ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS042i-sh22512D) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS042i-sh22512D ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS041i-sh22512A) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS043i-sh24472D ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS044i-sh24472K) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS044i-sh24472K ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS043i-sh24472D) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS045i-sh25642B ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS046i-sh25642C) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS046i-sh25642C ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS047i-sh25727B ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS048i-sh25727G) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS048i-sh25727G ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS047i-sh25727B) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS049i-sh2633B ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS050i-sh2633D) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS050i-sh2633D ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS049i-sh2633B) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS051i-sh2945A ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS052i-sh2945B) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS052i-sh2945B ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS051i-sh2945A) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS053i-sh3726A ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS054i-sh3726B) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS054i-sh3726B ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS053i-sh3726A) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS055i-sh4064A ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS056i-sh4064B) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS056i-sh4064B ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS055i-sh4064A) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS057i-sh4105B ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS058i-sh4105D) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS058i-sh4105D ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS057i-sh4105B) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS059i-sh4756A ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS060i-sh4756B) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS060i-sh4756B ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS059i-sh4756A) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS061i-sh521C ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS062i-sh521E) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS062i-sh521E ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS061i-sh521C) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS063i-sh554A ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS064i-sh554D) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS064i-sh554D ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS063i-sh554A) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS065i-sh921B ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS066i-sh921C) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS066i-sh921C ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS065i-sh921B) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS067i-sh9462A ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS068i-sh9462B) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS068i-sh9462B ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    An additional clone (FHS067i-sh9462A) is available from WiCell.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS069i-sh14564C ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.

  • FHS070i-sh4670A ( Induced pluripotent stem cell line )

    Application to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.

    The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.


Web Links:

Last updated: 2019-09-04T09:03:24.177-04:00

Copyright © 2016 by the President and Fellows of Harvard College
The eagle-i Consortium is supported by NIH Grant #5U24RR029825-02 / Copyright 2016